Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
- Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist Dimerix Limited (ASX: DXB)
- Mission will receive up to US$292 million in upfront and milestone payments, plus up to double-digit tiered royalties on global net sales
- Divestment validates Mission’s USP30 platform and provides non-dilutive capital to accelerate Mission’s lead CNS programme, MTX325, currently in Phase 1 clinical development for Parkinson’s disease
CAMBRIDGE, UK, 17 July 2026 – Mission Therapeutics Limited (“Mission”), a clinical-stage biotechnology company discovering and developing novel therapeutics to restore cellular health and function by promoting the removal of dysfunctional mitochondria, today announced the divestment of its Phase 2-ready novel first-in-class and best-in-class therapeutic candidate, MTX652, to Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company focused on renal disease, for initial development in Acute Kidney Injury (AKI).
